- 询价
- 2025年12月30日
15 年金牌会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 库存：
大量
- 细胞形态：
上皮样
- 器官来源：
肺
- 相关疾病：
小细胞肺癌
- ATCC Number：
HTB-175™
- 运输方式：
冻存运输
- 年限：
40 years
- 生长状态：
悬浮生长
- 物种来源：
人
- 是否是肿瘤细胞：
1
| Designations: | NCI-H82 [H82] | ||
| Depositors: | AF Gazdar, JD Minna | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | aggregates in suspension; the cells grow in very large aggregates, and the aggregates are the only viable cell population | ||
| Organism: | Homo sapiens | ||
| Morphology: | epithelial |
||
| Source: | Organ: lung Disease: carcinoma; small cell lung cancer Derived from metastatic site: pleural effusion |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Receptors: | insulin-like growth factor II (IGF II); atrial natriuretic peptide (ANP) | ||
| Tumorigenic: | Yes | ||
| Oncogene: | myc +; myb -; raf +; ras +; fms +; fes + | ||
| DNA Profile (STR): | Amelogenin: X CSF1PO: 11 D13S317: 8 D16S539: 12 D5S818: 12 D7S820: 10,13 THO1: 9,9.3 TPOX: 11 vWA: 14 |
||
| Cytogenetic Analysis: | This is a near triploid human cell line. The modal chromosome number is 58, occurring at 44% with polyploidy at 3%. Marker chromosomes der(1)t(1;709p13;p11), t(13q;?HSR;15q) and der(190t(19;?)(q13.4;?) were common to most cells., There were two distinct subpopulations readily distinguished by karyotype. Besides uniform changes in the numbers of copies of some normal chromosomes, one population had der(3)t(3;20)(p11;p11?), t(3q19p), i(7q) and a minute chromosome of unknown origin., The other had t(1q17p), del(1)(q21), der(3)t(3;7)(p12;q11) plus two other markers. Each cell had two copies of a normal X chromosome. The Y chromosome was not detected in Q banded preparations. | ||
| Isoenzymes: | AK-1, 1 ES-D, 1 G6PD, B GLO-I, 1 Me-2, 1 PGM1, 1-2 PGM3, 1-2 |
||
| Age: | 40 years | ||
| Gender: | male | ||
| Ethnicity: | Caucasian | ||
| Comments: | The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung. The morphology of the original tumor was not characteristic of SCLC. The line is a biochemical and morphological variant of SCLC that expresses neuron specific enolase and the brain isoenzyme of creatine kinase. It does not have detectable levels of L-DOPA decarboxylase or bombesin. The cells produce an abnormally sized p53 mRNA (3.7 kb). C-myc DNA sequences are amplified about 25 fold, and there is a 24 fold increase in c-myc RNA relative to normal cells. The cells are reported to express functional ANP receptors, but treatment with ANP does not alter their growth pattern. The cells stain positively for neurofilaments and vimentin. There is expression of v-fes, v-fms, Ha-ras, Ki-ras, N-ras and c-raf 1 mRNAs. |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
||
| Subculturing: | Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:5 is recommended Medium Renewal: 2 to 3 times per week This line grows as aggregates of cells in suspension. Culture can be maintained by addition of medium or by replacement of medium. Alternatively, the cells may be collected by centrifugation and dispersed into fresh medium. |
||
| Preservation: | Culture medium, 95%; DMSO, 5% | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 |
||
| References: | 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201 1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 22446: Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141 23042: Gazdar AF, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41: 2773-2777, 1981. PubMed: 6265067 23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 23057: Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258 23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 23104: Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389 32276: Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760 32287: Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验相关实验
都是贴壁细胞，在消化传代过程中，步骤如下：倒尽旧的培养液－＞用无血清的培养基清洗一两次－＞加入一定量的胰酶，置于37度培养箱中5--10分钟，使细胞悬浮－＞显微镜下观察，待细胞大部分变圆时，回到超静台－＞加入一定量的含血清的新培养液，以终止胰酶作用－＞反复吹打细胞－＞再置显微镜下观察，直到细胞全部悬浮起来－＞吸出一部分加入新的培养瓶中－＞最后再补充加入一定量新的培养液。注意： 1、吹细胞时尽量多吹边角儿，此处细胞生长的多。2、吸出细胞前要混匀，可以剧烈震荡培养瓶。3、我们用的是DMEM
A Modified Protocol for Bisulfite Genomic Sequencing of Difficult Samples
, are RARB2 -transfectants that were established in our laboratory (21 ). MM-1 was also established in our laboratory (6 ). NCI-H23, NCI-H82, NCI-H125, NCI-H157, NCI-H520, and NCI-H596 were supplied by Dr. Adi Gazdar (NCI, NIH, Bethesda, MD). NBE-E6 E7 (22
Science 子刊揭露遗传性肺癌亚型，我们离肺癌精准医疗还有多远？
Medicine 2021 年 1 月 27 号，来自美国国家癌症研究所（NCI）的 Anish Thomas 教授带领团队在 Science 子刊 Science Translational Medicine 上发表了题为 Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies 的研究
技术资料暂无技术资料 索取技术资料
NCI-H82
询价
